Compare INSM & GFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | GFI |
|---|---|---|
| Founded | 1988 | 1887 |
| Country | United States | South Africa |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 38.5B |
| IPO Year | 2000 | 2007 |
| Metric | INSM | GFI |
|---|---|---|
| Price | $197.05 | $43.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $180.94 | $40.48 |
| AVG Volume (30 Days) | 2.8M | ★ 3.1M |
| Earning Date | 10-30-2025 | 08-22-2025 |
| Dividend Yield | N/A | ★ 1.45% |
| EPS Growth | N/A | ★ 198.42 |
| EPS | N/A | ★ 2.08 |
| Revenue | $447,022,000.00 | ★ $6,555,200,000.00 |
| Revenue This Year | $43.10 | $65.12 |
| Revenue Next Year | $128.25 | $27.93 |
| P/E Ratio | ★ N/A | $21.36 |
| Revenue Growth | 30.34 | ★ 50.41 |
| 52 Week Low | $60.40 | $12.98 |
| 52 Week High | $212.75 | $47.18 |
| Indicator | INSM | GFI |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 55.43 |
| Support Level | $189.59 | $41.08 |
| Resistance Level | $206.69 | $44.32 |
| Average True Range (ATR) | 6.40 | 1.83 |
| MACD | -2.76 | 0.25 |
| Stochastic Oscillator | 30.20 | 66.45 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.